Anticonvulsants in Psychiatry: Nutrient Depletions Guide

Anticonvulsant medications have evolved from their original epilepsy applications to become essential tools in modern psychiatric care, with topiramate, gabapentin, and pregabalin representing a distinct subset that offers unique therapeutic benefits for bipolar disorder, impulse control disorders, and treatment-resistant conditions. According to the Comparative Toxicogenomics Database (CTD), these three psychiatric anticonvulsants demonstrate 44 gene interactions across 2,451 disease associations, highlighting their broad physiological impact beyond neurotransmitter modulation. Unlike traditional mood stabilizers such as lithium or valproate, this newer generation works through diverse mechanisms—[gabapentin](/medications/gabapentin) and [pregabalin](/medications/pregabalin) selectively bind to the α2δ subunit of voltage-gated calcium channels, while [topiramate](/medications/topiramate) simultaneously inhibits carbonic anhydrase, blocks sodium channels, and modulates GABA receptors. This mechanistic diversity translates into distinctly different nutrient depletion profiles compared to classic anticonvulsants, making targeted nutritional monitoring crucial for psychiatric patients who often require long-term treatment and may be taking multiple medications simultaneously. The psychiatric use of these agents has grown exponentially over the past two decades, with gabapentin prescriptions alone increasing by over 30% between 2020-2023, driven largely by its off-label use for anxiety and bipolar disorder.

The nutrient depletion patterns among these psychiatric anticonvulsants vary dramatically in both mechanism and clinical severity. [Topiramate](/medications/topiramate) presents the most complex and clinically significant depletion profile through its unique carbonic anhydrase inhibition, which disrupts bicarbonate and electrolyte balance, leading to metabolic acidosis in approximately 15-20% of users. This mechanism causes the characteristic 'dopamax' cognitive effects—word-finding difficulties, memory impairment, and concentration problems that patients describe as 'thinking through fog'—because metabolic acidosis directly impairs neuronal function. Topiramate's carbonic anhydrase inhibition also promotes calcium phosphate kidney stone formation in 1.5% of users, while its appetite-suppressing effects can lead to generalized nutrient malabsorption in patients who develop significant anorexia. The medication additionally depletes folate through mild dihydrofolate reductase inhibition, similar to lamotrigine but less severe than methotrexate. [Gabapentin](/medications/gabapentin) and [pregabalin](/medications/pregabalin) show markedly different depletion patterns, primarily affecting B vitamin metabolism through unclear mechanisms that may involve altered gut microbiome function or reduced dietary intake due to sedation. Both medications can modestly impact [vitamin D levels](/biomarkers/vitamin-d) by reducing physical activity and sun exposure, while their calcium channel effects may interfere with calcium-dependent enzymatic processes involved in vitamin activation.

Clinically, these nutrient depletions manifest as symptoms that often overlap with psychiatric conditions, creating diagnostic complexity for both patients and clinicians. CTD data reveals that topiramate shows 891 disease associations, reflecting its systemic metabolic effects, while pregabalin demonstrates 799 disease associations despite being considered relatively 'clean' pharmacologically. Patients taking topiramate frequently experience fatigue, hyperventilation, and cognitive dulling that stems directly from bicarbonate depletion rather than the underlying psychiatric condition. This distinction becomes critical because correcting metabolic acidosis through sodium bicarbonate or potassium citrate supplementation can dramatically improve cognitive symptoms without reducing the medication's psychiatric efficacy. For gabapentin and pregabalin users, the primary clinical concern shifts from nutrient depletion to weight gain, affecting 10-20% of patients and potentially exacerbating metabolic syndrome risk when combined with antipsychotics. Psychiatric populations face amplified risks due to polypharmacy patterns—a patient taking topiramate plus an antipsychotic faces compounded effects on metabolic function, while those on gabapentin with antidepressants may experience additive sedation that masks nutritional symptoms. Women of reproductive age require particular attention, as topiramate's folate depletion can increase neural tube defect risks, while the weight gain from gabapentin or pregabalin can worsen polycystic ovary syndrome in susceptible individuals.

Optimal monitoring for psychiatric patients on these anticonvulsants requires biomarker tracking that extends beyond standard psychiatric medication protocols. For topiramate users, [basic metabolic panels](/biomarkers/basic-metabolic-panel) should be checked every 3-6 months to monitor serum bicarbonate levels, with values below 20 mEq/L indicating clinically significant acidosis requiring intervention. Annual [folate testing](/biomarkers/folate) becomes essential, particularly for women of childbearing age, with target levels maintained above 15 ng/mL through L-methylfolate supplementation. For all three medications, [vitamin D monitoring](/biomarkers/vitamin-d) should occur annually, with optimal levels maintained between 40-60 ng/mL rather than the standard 30 ng/mL minimum. Weight monitoring protocols differ by medication—monthly tracking for topiramate users to prevent dangerous weight loss, particularly in patients with eating disorders, and quarterly monitoring for gabapentin/pregabalin users to manage weight gain through early dietary intervention. The 24 gene interactions documented for gabapentin in CTD suggest genetic factors influence individual response patterns, making personalized monitoring increasingly important as pharmacogenomic testing becomes more accessible for psychiatric applications.